Zarontin and Seizures - a phase IV clinical study of FDA data

Summary:

Seizures is reported as a side effect among people who take Zarontin (ethosuximide), especially for people who are male, 50-59 old, have been taking the drug for 2 - 5 years also take Keppra, and have High blood pressure.

The phase IV clinical study analyzes which people have Seizures when taking Zarontin. It is created by eHealthMe based on reports of 958 people who have side effects when taking Zarontin from the FDA, and is updated regularly.

What is Zarontin?

Zarontin has active ingredients of ethosuximide. It is often used in petit mal seizure. eHealthMe is studying from 987 Zarontin users. Check the latest studies of Zarontin.

What is Seizures?

Seizures (abnormal excessive or synchronous neuronal activity in the brain) is found to be associated with 1,993 drugs and 2,279 conditions by eHealthMe. Check the latest studies of Seizures.

On Aug, 01, 2026

958 people reported to have side effects when taking Zarontin.
Among them, 131 people (13.67%) have Seizures.

Among these 131 people:

* Approximation only. Some reports may have incomplete information.

Do you take Zarontin and have Seizures?

- Check whether Seizures is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zarontin:

Zarontin (987 reports)

Seizures treatments and more:

Seizures (150,179 reports)

How severe was Seizures and when was it recovered:

Seizures in Zarontin

Expand to all the drugs that have ingredients of ethosuximide:

Seizures and drugs with ingredients of ethosuximide (315 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zarontin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Seizures:

Seizures (1,993 drugs)

Browse all the conditions that are associated with Seizures:

Seizures (2,279 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ethosuximide (the active ingredients of Zarontin) and Zarontin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.